Is dacomitinib/dacomitinib a domestic drug or an imported drug?

Dacomitinib/Dacomitinib (Dacomitinib) was first developed and produced by Pfizer, a world-renowned pharmaceutical company, so its market positioning is as an imported original drug. The drug was first approved by the US FDA in 2018 and was subsequently officially launched in China, providing a new treatment option for patients with EGFR mutant non-small cell lung cancer (NSCLC). Since it is an original drug, its initial supply in China mainly relies on imported channels, and the drug price is relatively high.

However, with China's rapid development in the field of drug research and development and the country's continuous support for innovative drugs and generic drug policies, some pharmaceutical companies have begun to develop domestic generic versions of dacomitinib. At present, there are indeed some R&D projects for dacomitinib generic drugs in China, and they are gradually advancing in terms of consistency evaluation and production qualifications. However, the number of domestic generic drugs that have actually been approved and put on the market is limited. Overall, clinically, patients are still most exposed to imported original drugs.

There is essentially no ingredient difference between imported original drugs and domestic generic drugs. Generic drugs need to pass strict quality and efficacy consistency evaluations before they can be put on the market. In other words, if domestic generic drugs are put on the market in batches in the future, they can further reduce patients' medication burden while ensuring safety and efficacy, so that more patients can afford treatment.

It is worth noting that dacomitinib has been included in the domestic medical insurance catalog, which means that even if the original drug is imported, the financial pressure on patients has been significantly alleviated. The implementation of this policy has positive significance for improving patient compliance and treatment effects.

Therefore, in a strict sense, dacomitinib is an imported original drug. However, with the active follow-up of domestic pharmaceutical companies, domestic generic drugs are expected to gradually enter the market in the future, providing patients with more options.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro